Advertisement

Topics

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 60-page report is available in PDF from $2000.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 6
Therapeutics Development 7
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 7
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis 8
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 9
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 13
CTI BioPharma Corp. 13
Gilead Sciences, Inc. 14
Incyte Corporation 15
Italfarmaco S.p.A. 16
Nippon Shinyaku Co., Ltd. 17
Novartis AG 18
Promedior, Inc. 19
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
buparlisib hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
givinostat - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
INCB-39110 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LCL-161 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NS-018 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pacritinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PRM-151 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
simtuzumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Recent Pipeline Updates 46
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects 57
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

For more information open Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015.

SKU: GMDHC6617IDB

Original Article: Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...